Status:
COMPLETED
Prevalence of Hypogonadism in Male Cancer Patients
Lead Sponsor:
Baylor College of Medicine
Collaborating Sponsors:
Michael E. DeBakey VA Medical Center
Solvay Pharmaceuticals
Conditions:
Cancer
Hypogonadism
Eligibility:
MALE
18+ years
Brief Summary
Cancer and its complications are common problems. In most cases, this condition has a profound impact on survival and quality of life (QoL). Fatigue, sexual dysfunction, decreased sexual drive, depres...
Eligibility Criteria
Inclusion
- Male subjects ≥ 18 years of age with histological diagnosis of cancer for cancer group.
- Provide written informed consent prior to screening.
- Histological diagnosis of cancer other than non-melanoma skin cancer for the two cancer groups.
Exclusion
- Concomitant use of GH, Megestrol, Marinol, or any other anabolic agent, appetite stimulant (including corticosteroids other than dexamethasone at the time of IV chemotherapy administrations), tube feedings, or parenteral nutrition during the 3 months prior to entering the study.
- Participation in a clinical trial with investigational agents within 1 month of enrollment.
- Prior or current use of other medications that interfere with gonadal axis (androgens, estrogens, anti-androgens, etc).
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 2 2020
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT00472940
Start Date
November 1 2006
End Date
September 2 2020
Last Update
November 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas, United States, 77030